Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sara Edwards

Nurse Practitioner, Acute Care Maywood, IL Nurse Practitioner

NPI 1942518428 CMS profile 10820199

2160 S 1St Ave, Maywood, IL 60153

Open in the dashboard

General payments

$8,556

87 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Edwards of Maywood, IL is reported in the CMS Open Payments database as having received $8,556 across 87 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $369 13
2024 General $1,660 21
2023 General $5,718 30
2022 General $406 16
2021 General $404 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Edwards
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Sara Edwards were reported at $369. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Sara Edwards Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $404 $123 $38–$327 $132
2022 $406 $130 $44–$369 $149
2023 $5,718 $144 $49–$410 $160
2024 $1,660 $146 $48–$433 $164
2025 $369 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $5,546 20 payments
  2. Abbott Laboratories $2,151 45 payments
  3. Abiomed $183 4 payments
  4. Impulse Dynamics (USA) Inc. $176 1 payment
  5. CHF Solutions, Inc $132 1 payment
  6. Novartis Pharmaceuticals Corporation $107 5 payments
  7. Merck Sharp & Dohme Corporation $40 2 payments
  8. Scpharmaceuticals Inc. $38 2 payments
  9. BridgeBio Pharma, Inc. $37 1 payment
  10. CVRx, Inc. $30 1 payment
  11. Other $116 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,107 1 payment
  2. Food and Beverage $2,824 72 payments
  3. Travel and Lodging $2,212 12 payments
  4. Education $281 1 payment
  5. Compensation for serving as faculty or as a speaker for a medical education program $132 1 payment
Products named General payments · program years 2021–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $1,801 28 payments
  2. HeartWare HVAD $306 2 payments
  3. OPTIMIZER Cardiovascular Device $176 1 payment
  4. OPTIMIZER Cardiovascular Device $176 1 payment
  5. Impella $160 3 payments
  6. AQUADEX SMARTFLOW CONSOLE $132 1 payment
  7. ENTRESTO $107 5 payments
  8. HeartMate 3 Left Ventricular Assist Device $76 4 payments
  9. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $74 3 payments
  10. CARDIOMEMS $70 4 payments
  11. Other $496 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

87

Median for Nurse Practitioner: 389

Drug cost

$18,809

Median for Nurse Practitioner: $21,885

Branded share of claims

12.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 11 $16,875
Amiodarone Hcl Generic 20 $961
Warfarin Sodium Generic 32 $558
Digoxin Generic 12 $210
Spironolactone Generic 12 $204

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record